Sana Biotechnology's Hypoimmune Cell Therapy Shows Promise in Type 1 Diabetes
• Sana Biotechnology's UP421 demonstrated survival and function of transplanted pancreatic beta cells in a type 1 diabetes patient without immunosuppression.
• The first-in-human study showed increased C-peptide levels, indicating insulin production, and sustained signals at the transplant site via MRI.
• TD Cowen upgraded Sana Biotechnology to Buy, noting the results meaningfully derisk type 1 diabetes and other applications of the Hypoimmune platform.
• The company's stock price surged following the release of the positive data, reflecting investor optimism about the potential of the new treatment.
FDA Approves Bavarian Nordic's Vimkunya, First Chikungunya Vaccine for Adolescents
• The FDA has approved Vimkunya, a chikungunya vaccine developed by Bavarian Nordic, for individuals aged 12 and older.
• Vimkunya is the first virus-like particle (VLP) single-dose chikungunya vaccine approved in the U.S., offering a new preventative option.
• Clinical trials showed Vimkunya induced neutralizing antibodies in up to 97.8% of vaccinated individuals within 21 days.
• Commercial availability of Vimkunya in the U.S. is expected in the first half of 2025, with launches in key European markets anticipated.
MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers
• MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs).
• The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients.
• EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment.
• An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.
Fish-Skin Grafts Show Superior Healing in Diabetic Foot Ulcers
• A clinical study reveals that fish-skin grafts significantly improve healing rates in diabetic foot ulcers compared to standard care.
• The fish-skin treatment led to a 44% healing rate after 16 weeks, versus 26% with standard methods, according to the NEJM published study.
• Kerecis' fish-skin grafts, derived from Atlantic cod, offer a viral transfer risk-free alternative with regenerative properties.
• Coloplast acquired Kerecis for $1.3 billion, recognizing its rapid growth in the biologics wound care sector.
© Copyright 2025. All Rights Reserved by MedPath